Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Catharina Ziekenhuis Eindhoven
Assistance Publique - Hôpitaux de Paris
Alliance for Clinical Trials in Oncology
Zhejiang University
Clinique Paris-Bercy
UNICANCER
Northwestern University
OHSU Knight Cancer Institute
Sorlandet Hospital HF
University of Minnesota
Memorial University of Newfoundland
Alaska Native Tribal Health Consortium
VA Office of Research and Development
Emory University
Dartmouth-Hitchcock Medical Center
Chinese University of Hong Kong
Uppsala University Hospital
University of California, San Diego
Hospital Clinic of Barcelona
Hospital Universitario de Móstoles
Asociación Española de GastroenterologÃa
Jubaan Ltd.
Institut Investigacio Sanitaria Pere Virgili
Odin Medical
State Scientific Centre of Coloproctology, Russian Federation
National Taiwan University Hospital
Singlera Genomics Inc.
Egymedicalpedia
Columbia University
Persephone Biosciences
Hospital Mutua de Terrassa
Institute of Gastroenterology and Advance Endoscopy
Hospital Universitario La Fe
Exact Sciences Corporation
Rush University Medical Center
Military University Hospital, Prague
Istanbul Medipol University Hospital
Hospital Frydek-Mistek
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mayo Clinic
University of Tabuk
Centre hospitalier de l'Université de Montréal (CHUM)
Hospital Provincial de Castellon
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Parc de Salut Mar
Centre Hospitalier Sud Francilien